8-K: Oncocyte Corporation Enters $7.5 Million At-The-Market Sales Agreement with Needham & Company, LLC

Oncocyte Corporation has entered into a sales agreement with Needham & Company, LLC to potentially sell up to $7.5 million of its common stock through an at-the-market offering.

Summary

• On August 9, 2024, Oncocyte Corporation entered into a sales agreement with Needham & Company, LLC, allowing the company to sell up to $7.5 million of its common stock.
• The shares will be sold through an at-the-market offering, as defined by Rule 415 of the Securities Act.
• Needham & Company will act as the sales agent, using commercially reasonable efforts to sell the shares.
• Oncocyte has the option to sell shares to Needham & Company as principal in negotiated transactions.
• The company is not obligated to sell any shares and can suspend or terminate the agreement at any time.
• The net proceeds from the offering will be used for working capital and other general corporate purposes.
• The sales agreement will terminate upon the sale of all shares or termination by either party.
• Oncocyte will pay Needham & Company a 3.0% commission on the gross proceeds from each sale.
• The company also terminated its previous at-the-market sales agreement with BTIG, LLC, which had a $50 million program.

Sentiment

Score: 6

Explanation: The document is neutral to slightly positive. While it details a capital raise, which can be dilutive, it also provides the company with necessary funds for operations. The terms are standard for this type of offering.

Positives

• The new sales agreement provides Oncocyte with a flexible way to raise capital.
• The at-the-market offering allows the company to sell shares gradually, potentially minimizing market impact.
• The termination of the previous agreement with BTIG, LLC streamlines the company's capital raising efforts.

Negatives

• The company will incur a 3.0% commission on each sale of shares, reducing the net proceeds.
• The at-the-market offering could potentially dilute existing shareholders if a large number of shares are sold.
• The company is not obligated to sell any shares, so there is no guarantee of raising the full $7.5 million.

Risks

• The company may not be able to sell all of the $7.5 million in shares.
• The market price of the company's stock could be negatively impacted by the at-the-market offering.
• The company's reliance on at-the-market offerings for capital could indicate financial challenges.

Future Outlook

The company intends to use the net proceeds from this offering for working capital and other general corporate purposes.

Management Comments

• The document does not contain any direct quotes from management.

Industry Context

At-the-market offerings are a common method for publicly traded companies to raise capital, particularly for smaller companies or those with volatile stock prices. This allows for a more flexible approach to raising funds compared to traditional underwritten offerings.

Comparison to Industry Standards

• The 3.0% commission is within the typical range for at-the-market offerings.
• The $7.5 million offering size is relatively small, suggesting the company may be seeking to raise capital without significantly diluting existing shareholders.
• The termination of the previous agreement with BTIG, LLC and the entry into a new agreement with Needham & Company, LLC is not unusual as companies often change their financial partners.

Stakeholder Impact

• Shareholders may experience dilution if a large number of shares are sold.
• The company will have additional working capital to fund operations.
• The company's financial position may be strengthened by the capital raise.

Next Steps

• Oncocyte will begin selling shares through Needham & Company, LLC as needed.
• The company will use the net proceeds for working capital and other general corporate purposes.
• The company will file a prospectus supplement with the SEC detailing the sales.

Key Dates

Keywords

at-the-market offering, sales agreement, common stock, Needham & Company, capital raise, working capital, Oncocyte Corporation, placement shares, BTIG, equity financing